Home » Topics » BioWorld Science, Infection

BioWorld Science, Infection
RSS

SK Chemical's NBP607-QIV effective in phase III influenza study

Nov. 2, 2016

Cempra receives milestone payment from Toyama Chemical

Nov. 2, 2016

IURTC presents anti-HBV agents

Nov. 2, 2016

MSD files for approval of bezlotoxumab in Japan

Oct. 31, 2016

GlaxoSmithKline's gepotidacin effective in phase II trial for skin and skin structure infections

Oct. 31, 2016

ReViral initiates phase I trial of RV-521 to treat RSV

Oct. 31, 2016

Shionogi's cefiderocol demonstrates potential for biothreat pathogens

Oct. 31, 2016

KBP Bioscience's antibiotic KBP-7072 evaluated in phase I trial

Oct. 31, 2016

Entasis Therapeutics starts phase I trial of ETX-2514

Oct. 27, 2016

Debiopharm International completes phase II trial of Debio-1450

Oct. 27, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance
BioWorld
It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...